5 years ago

MiNA Therapeutics Secures £23 Million Series A Funding to Advance RNA Activation Therapeutics

  • MiNA Therapeutics, a UK-based company developing RNA activation therapeutics, has secured £23 million in Series A funding led by aMoon

  • The funding will advance the company's pipeline of saRNA therapeutics and support clinical development of its lead candidate, MTL-CEBPA, a combination treatment for cancer

  • MTL-CEBPA has demonstrated positive initial results in clinical trials for advanced liver cancer, showing improved response rates when combined with sorafenib

  • The funding will allow MiNA Therapeutics to conduct a Phase 2 study of MTL-CEBPA in combination with sorafenib for advanced liver cancer and a Phase I/Ib study in combination with pembrolizumab for advanced solid tumor malignancies

  • It will also support research for new saRNA therapies for cancer, metabolic, and genetic diseases.

      • ProblemHealthcare

      "Cancer patients face challenges with current treatment options, often experiencing limited effectiveness and adverse side effects."

      Solution

      "MiNA Therapeutics is developing a novel RNA activation therapy to enhance the body's immune response against tumors, potentially improving treatment outcomes and reducing side effects."

      Covered on